Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription Articles published in Nat Med Retrieve available abstracts of 112 articles: HTML format

Single Articles

April 2024
1. SARAF A, Gurjar R, Kaviraj S, Kulkarni A, et al
   An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
   Nat Med. 2024 Apr 18. doi: 10.1038/s41591-024-02955.
   PubMed     Abstract available
   
   
   
2. ARNOLD C
   'Inverse vaccines' could treat autoimmune disease - from multiple sclerosis to celiac disease.
   Nat Med. 2024 Apr 10. doi: 10.1038/d41591-024-00024.
   PubMed    
   
   
   
3. YARCHOAN M, Gane EJ, Marron TU, Perales-Linares R, et al
   Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
   Nat Med. 2024 Apr 7. doi: 10.1038/s41591-024-02894.
   PubMed     Abstract available
   
   
   
4. 
   Systematic testing in cholera surveillance enhances vaccine impact and cost-effectiveness.
   Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02907.
   PubMed    
   
   
   March 2024
5. O'LEARY K
   Going the extra mile to increase vaccine uptake.
   Nat Med. 2024 Mar 28. doi: 10.1038/d41591-024-00022.
   PubMed    
   
   
   
6. RAPPAPORT AR, Kyi C, Lane M, Hart MG, et al
   A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
   Nat Med. 2024 Mar 27. doi: 10.1038/s41591-024-02851.
   PubMed     Abstract available
   
   
   
7. XU H, Zou K, Dent J, Wiens KE, et al
   Enhanced cholera surveillance to improve vaccination campaign efficiency.
   Nat Med. 2024 Mar 5. doi: 10.1038/s41591-024-02852.
   PubMed     Abstract available
   
   
   February 2024
8. PERETTI-WATEL P, Verger P, Ward JK
   To understand mRNA vaccine hesitancy, stop calling the public anti-science.
   Nat Med. 2024 Feb 27. doi: 10.1038/s41591-024-02816.
   PubMed    
   
   
   January 2024
9. O'LEARY K
   Personalized mRNA vaccine boosts melanoma immunotherapy.
   Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
   PubMed    
   
   
   
10. TAYLOR TE, Osier F
    Integrating vaccines and monoclonal antibodies into malaria prevention.
    Nat Med. 2024 Jan 10. doi: 10.1038/s41591-023-02745.
    PubMed    
    
    
    
11. PANT S, Wainberg ZA, Weekes CD, Furqan M, et al
    Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
    Nat Med. 2024 Jan 9. doi: 10.1038/s41591-023-02760.
    PubMed     Abstract available
    
    
    December 2023
12. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    Author Correction: Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.
    Nat Med. 2023 Dec 22. doi: 10.1038/s41591-023-02772.
    PubMed    
    
    
    
13. BARNABAS RV, Brown ER, Onono MA, Bukusi EA, et al
    Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results.
    Nat Med. 2023 Dec 4. doi: 10.1038/s41591-023-02658.
    PubMed     Abstract available
    
    
    November 2023
14. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.
    Nat Med. 2023 Nov 27. doi: 10.1038/s41591-023-02670.
    PubMed     Abstract available
    
    
    
15. O'LEARY K
    A new, affordable HPV vaccine.
    Nat Med. 2023 Nov 13. doi: 10.1038/d41591-023-00095.
    PubMed    
    
    
    
16. SCHOMMERS P, Kim DS, Schlotz M, Kreer C, et al
    Dynamics and durability of HIV-1 neutralization are determined by viral replication.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02582.
    PubMed     Abstract available
    
    
    
17. CHEHRAZI-RAFFLE A, Budde LE, Pal SK
    Boosting CAR T cells with anti-tumor mRNA vaccines.
    Nat Med. 2023 Nov 6. doi: 10.1038/s41591-023-02623.
    PubMed    
    
    
    October 2023
18. LAU JJ, Cheng SMS, Leung K, Lee CK, et al
    Author Correction: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
    Nat Med. 2023 Oct 24. doi: 10.1038/s41591-023-02648.
    PubMed    
    
    
    
19. MACKENSEN A, Haanen JBAG, Koenecke C, Alsdorf W, et al
    CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.
    Nat Med. 2023 Oct 23. doi: 10.1038/s41591-023-02612.
    PubMed     Abstract available
    
    
    September 2023
20. GRASSL N, Poschke I, Lindner K, Bunse L, et al
    A H3K27M-targeted vaccine in adults with diffuse midline glioma.
    Nat Med. 2023 Sep 21. doi: 10.1038/s41591-023-02555.
    PubMed     Abstract available
    
    
    August 2023
21. CHALKIAS S, Whatley JL, Eder F, Essink B, et al
    Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
    Nat Med. 2023 Aug 31. doi: 10.1038/s41591-023-02517.
    PubMed     Abstract available
    
    
    
22. BRANCHE AR, Rouphael NG, Diemert DJ, Falsey AR, et al
    Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
    Nat Med. 2023 Aug 28. doi: 10.1038/s41591-023-02503.
    PubMed     Abstract available
    
    
    
23. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    PubMed    
    
    
    
24. JOHNSON B
    GSK's gonorrhea vaccine receives fast-track designation to expedite clinical trials.
    Nat Med. 2023 Aug 7. doi: 10.1038/d41591-023-00069.
    PubMed    
    
    
    July 2023
25. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A
    Community-engaged Mpox vaccination provides lessons for equitable health care in the United States.
    Nat Med. 2023 Jul 19. doi: 10.1038/s41591-023-02447.
    PubMed    
    
    
    
26. BARNES E, Goodyear CS, Willicombe M, Gaskell C, et al
    SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02414.
    PubMed     Abstract available
    
    
    
27. BERKLEY S
    The poorest and most vulnerable communities should be the first to be vaccinated.
    Nat Med. 2023;29:1596.
    PubMed    
    
    
    June 2023
28. 
    Precision medicine meets cancer vaccines.
    Nat Med. 2023;29:1287.
    PubMed    
    
    
    May 2023
29. VAN DER KLAAUW AA, Horner EC, Pereyra-Gerber P, Agrawal U, et al
    Accelerated waning of the humoral response to COVID-19 vaccines in obesity.
    Nat Med. 2023 May 11. doi: 10.1038/s41591-023-02343.
    PubMed     Abstract available
    
    
    March 2023
30. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Author Correction: Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2023 Mar 27:1. doi: 10.1038/s41591-023-02303.
    PubMed    
    
    
    
31. STAMM TA, Partheymuller J, Mosor E, Ritschl V, et al
    Determinants of COVID-19 vaccine fatigue.
    Nat Med. 2023 Mar 27. doi: 10.1038/s41591-023-02282.
    PubMed     Abstract available
    
    
    
32. LIPSCHUETZ M, Guedalia J, Cohen SM, Sompolinsky Y, et al
    Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization.
    Nat Med. 2023 Mar 23. doi: 10.1038/s41591-023-02270.
    PubMed     Abstract available
    
    
    
33. KHOURY DS, Docken SS, Subbarao K, Kent SJ, et al
    Predicting the efficacy of variant-modified COVID-19 vaccine boosters.
    Nat Med. 2023 Mar 2. doi: 10.1038/s41591-023-02228.
    PubMed     Abstract available
    
    
    February 2023
34. GRANT R, Sacks JA, Abraham P, Chunsuttiwat S, et al
    When to update COVID-19 vaccine composition.
    Nat Med. 2023 Feb 20. doi: 10.1038/s41591-023-02220.
    PubMed    
    
    
    
35. CARVALHO T
    mRNA vaccine effective against RSV respiratory disease.
    Nat Med. 2023 Feb 15. doi: 10.1038/d41591-023-00017.
    PubMed    
    
    
    January 2023
36. SAGY YW, Zucker R, Hammerman A, Markovits H, et al
    Real-world effectiveness of a single dose of mpox vaccine in males.
    Nat Med. 2023 Jan 31. doi: 10.1038/s41591-023-02229.
    PubMed     Abstract available
    
    
    
37. WANG G, Yao Y, Wang Y, Gong J, et al
    Determinants of COVID-19 vaccination status and hesitancy among older adults in China.
    Nat Med. 2023 Jan 31. doi: 10.1038/s41591-023-02241.
    PubMed     Abstract available
    
    
    
38. O'LEARY K
    Cash rewards for vaccination.
    Nat Med. 2023 Jan 26. doi: 10.1038/d41591-023-00011.
    PubMed    
    
    
    
39. LAU JJ, Cheng SMS, Leung K, Lee CK, et al
    Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
    Nat Med. 2023 Jan 18. doi: 10.1038/s41591-023-02219.
    PubMed     Abstract available
    
    
    
40. LAZARUS JV, Wyka K, White TM, Picchio CA, et al
    A survey of COVID-19 vaccine acceptance across 23 countries in 2022.
    Nat Med. 2023 Jan 9. doi: 10.1038/s41591-022-02185.
    PubMed     Abstract available
    
    
    
41. OGONGO P, Ernst JD
    Finding antigens for TB vaccines: the good, the bad and the useless.
    Nat Med. 2023 Jan 5. doi: 10.1038/s41591-022-02123.
    PubMed    
    
    
    December 2022
42. KURHADE C, Zou J, Xia H, Liu M, et al
    Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster.
    Nat Med. 2022 Dec 6. doi: 10.1038/s41591-022-02162.
    PubMed     Abstract available
    
    
    
43. O'LEARY K
    The next generation of COVID-19 vaccines.
    Nat Med. 2022;28:2450.
    PubMed    
    
    
    November 2022
44. O'LEARY K
    A universal flu vaccine on the horizon.
    Nat Med. 2022 Nov 30. doi: 10.1038/d41591-022-00113.
    PubMed    
    
    
    
45. 
    Quantifying the effect of inequitable global vaccine coverage on the COVID-19 pandemic.
    Nat Med. 2022 Nov 4. pii: 10.1038/s41591-022-02065.
    PubMed    
    
    
    
46. CARVALHO T
    Intranasal COVID-19 vaccine fails to induce mucosal immunity.
    Nat Med. 2022 Nov 3. pii: 10.1038/d41591-022-00106.
    PubMed    
    
    
    October 2022
47. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02064.
    PubMed     Abstract available
    
    
    
48. BAILON L, Llano A, Cedeno S, Escriba T, et al
    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02060.
    PubMed     Abstract available
    
    
    
49. SCHEAFFER SM, Lee D, Whitener B, Ying B, et al
    Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Nat Med. 2022 Oct 20. pii: 10.1038/s41591-022-02092.
    PubMed     Abstract available
    
    
    
50. ZAECK LM, Lamers MM, Verstrepen BE, Bestebroer TM, et al
    Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals.
    Nat Med. 2022 Oct 18. pii: 10.1038/s41591-022-02090.
    PubMed     Abstract available
    
    
    
51. MENTZER AJ, O'Connor D, Bibi S, Chelysheva I, et al
    Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02078.
    PubMed     Abstract available
    
    
    
52. BHATTACHARYA D, Victora GD
    Boosting with updated COVID-19 mRNA vaccines.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02048.
    PubMed    
    
    
    
53. CHALKIAS S, Eder F, Essink B, Khetan S, et al
    Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02031.
    PubMed     Abstract available
    
    
    September 2022
54. CARVALHO T
    mRNA vaccines boost BioNTech's CAR T cell therapy.
    Nat Med. 2022 Sep 1. pii: 10.1038/d41591-022-00091.
    PubMed    
    
    
    August 2022
55. PALMER CD, Rappaport AR, Davis MJ, Hart MG, et al
    Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2022;28:1619-1629.
    PubMed     Abstract available
    
    
    July 2022
56. LUONG NGUYEN LB, Ghosn J, Durier C, Tachot C, et al
    A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.
    Nat Med. 2022 Jul 13. pii: 10.1038/d41591-022-00077.
    PubMed    
    
    
    
57. JARA A, Undurraga EA, Zubizarreta JR, Gonzalez C, et al
    Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.
    Nat Med. 2022;28:1377-1380.
    PubMed     Abstract available
    
    
    June 2022
58. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01876.
    PubMed    
    
    
    
59. CAO L, Lou J, Chan SY, Zheng H, et al
    Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01877.
    PubMed     Abstract available
    
    
    May 2022
60. O'LEARY K
    Finding a vaccine for Epstein-Barr virus.
    Nat Med. 2022 May 19. pii: 10.1038/d41591-022-00061.
    PubMed    
    
    
    
61. MOLINO D, Durier C, Radenne A, Desaint C, et al
    A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.
    Nat Med. 2022 May 5. pii: 10.1038/s41591-022-01785.
    PubMed    
    
    
    
62. CHU L, Vrbicky K, Montefiori D, Huang W, et al
    Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
    Nat Med. 2022;28:1042-1049.
    PubMed     Abstract available
    
    
    
63. TSENG HF, Ackerson BK, Luo Y, Sy LS, et al
    Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
    Nat Med. 2022;28:1063-1071.
    PubMed     Abstract available
    
    
    April 2022
64. O'LEARY K
    Single vaccine shot protects against cervical cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00056.
    PubMed    
    
    
    
65. ARBEL R, Sergienko R, Friger M, Peretz A, et al
    Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
    Nat Med. 2022 Apr 25. pii: 10.1038/s41591-022-01832.
    PubMed     Abstract available
    
    
    
66. PUHACH O, Adea K, Hulo N, Sattonnet P, et al
    Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
    Nat Med. 2022 Apr 8. pii: 10.1038/s41591-022-01816.
    PubMed     Abstract available
    
    
    
67. PAJON R, Paila YD, Girard B, Dixon G, et al
    Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.
    Nat Med. 2022;28:823-830.
    PubMed     Abstract available
    
    
    March 2022
68. WEBSTER P
    Russian COVID-19 vaccine in jeopardy after Ukraine invasion.
    Nat Med. 2022 Mar 15. pii: 10.1038/d41591-022-00042.
    PubMed    
    
    
    
69. PERTWEE E, Simas C, Larson HJ
    An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy.
    Nat Med. 2022 Mar 10. pii: 10.1038/s41591-022-01728.
    PubMed     Abstract available
    
    
    
70. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2022 Mar 8. pii: 10.1038/s41591-022-01771.
    PubMed    
    
    
    
71. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
    mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Nat Med. 2022;28:477-480.
    PubMed     Abstract available
    
    
    
72. GAO Y, Cai C, Grifoni A, Muller TR, et al
    Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
    Nat Med. 2022;28:472-476.
    PubMed     Abstract available
    
    
    February 2022
73. DU Z, Wang L, Pandey A, Lim WW, et al
    Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
    Nat Med. 2022 Feb 24. pii: 10.1038/s41591-022-01736.
    PubMed     Abstract available
    
    
    
74. AULADELL M, Phuong HVM, Mai LTQ, Tseng YY, et al
    Influenza virus infection history shapes antibody responses to influenza vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-022-01690.
    PubMed     Abstract available
    
    
    
75. VALKENBURG SA, Poon LLM
    Exploring the landscape of immune responses to influenza infection and vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-021-01656.
    PubMed    
    
    
    
76. WEI J, Pouwels KB, Stoesser N, Matthews PC, et al
    Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
    Nat Med. 2022 Feb 14. pii: 10.1038/s41591-022-01721.
    PubMed     Abstract available
    
    
    
77. CERQUEIRA-SILVA T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, et al
    Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
    Nat Med. 2022 Feb 9. pii: 10.1038/s41591-022-01701.
    PubMed     Abstract available
    
    
    
78. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    Author Correction: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Feb 4. pii: 10.1038/s41591-022-01730.
    PubMed    
    
    
    
79. ANDREWS SF, Raab JE, Gorman J, Gillespie RA, et al
    A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01636.
    PubMed     Abstract available
    
    
    
80. HOUSER KV, Chen GL, Carter C, Crank MC, et al
    Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01660.
    PubMed     Abstract available
    
    
    January 2022
81. WRATIL PR, Stern M, Priller A, Willmann A, et al
    Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
    Nat Med. 2022 Jan 28. pii: 10.1038/s41591-022-01715.
    PubMed     Abstract available
    
    
    
82. LI J, Hou L, Guo X, Jin P, et al
    Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Nat Med. 2022 Jan 27. pii: 10.1038/s41591-021-01677.
    PubMed     Abstract available
    
    
    
83. PEREZ-THEN E, Lucas C, Monteiro VS, Miric M, et al
    Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01705.
    PubMed     Abstract available
    
    
    
84. CHENG SMS, Mok CKP, Leung YWY, Ng SS, et al
    Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01704.
    PubMed     Abstract available
    
    
    
85. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England.
    Nat Med. 2022 Jan 14. pii: 10.1038/s41591-022-01699.
    PubMed     Abstract available
    
    
    
86. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Jan 13. pii: 10.1038/s41591-021-01666.
    PubMed     Abstract available
    
    
    
87. WARD JK, Gauna F, Gagneux-Brunon A, Botelho-Nevers E, et al
    The French health pass holds lessons for mandatory COVID-19 vaccination.
    Nat Med. 2022 Jan 12. pii: 10.1038/s41591-021-01661.
    PubMed    
    
    
    
88. ETIENNE CF
    COVID-19 has revealed a pandemic of inequality.
    Nat Med. 2022;28:17.
    PubMed    
    
    
    December 2021
89. PATONE M, Mei XW, Handunnetthi L, Dixon S, et al
    Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Nat Med. 2021 Dec 14. pii: 10.1038/s41591-021-01630.
    PubMed     Abstract available
    
    
    
90. ADEPOJU P
    As COVID-19 vaccines arrive in Africa, Omicron is reducing supply and increasing demand.
    Nat Med. 2021 Dec 13. pii: 10.1038/d41591-021-00073.
    PubMed    
    
    
    
91. 
    Vaccine development needs a boost.
    Nat Med. 2021 Dec 2. pii: 10.1038/s41591-021-01633.
    PubMed    
    
    
    
92. O'LEARY K
    A malaria vaccine at last.
    Nat Med. 2021;27:2057.
    PubMed    
    
    
    
93. MORRIS L
    mRNA vaccines offer hope for HIV.
    Nat Med. 2021;27:2082-2084.
    PubMed    
    
    
    
94. ZHANG P, Narayanan E, Liu Q, Tsybovsky Y, et al
    A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Nat Med. 2021;27:2234-2245.
    PubMed     Abstract available
    
    
    
95. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2021;27:2212-2223.
    PubMed     Abstract available
    
    
    
96. VAN KERKHOVE MD
    COVID-19 in 2022: controlling the pandemic is within our grasp.
    Nat Med. 2021;27:2070.
    PubMed    
    
    
    
97. WEBSTER P
    COVID-19 timeline of events.
    Nat Med. 2021;27:2054-2055.
    PubMed    
    
    
    
98. MAY M
    Eight unanswered questions about the COVID-19 pandemic.
    Nat Med. 2021;27:2058-2061.
    PubMed    
    
    
    
99. ARNOLD C
    11 clinical trials that will shape medicine in 2022.
    Nat Med. 2021;27:2062-2064.
    PubMed    
    
    
    November 2021
100. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
     Publisher Correction: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
     Nat Med. 2021 Nov 29. pii: 10.1038/s41591-021-01644.
     PubMed    
     
     
     
101. O'LEARY K
     An mRNA vaccine against tick bites.
     Nat Med. 2021 Nov 25. pii: 10.1038/d41591-021-00071.
     PubMed    
     
     
     
102. JUNO JA, Wheatley AK
     Boosting immunity to COVID-19 vaccines.
     Nat Med. 2021 Nov 11. pii: 10.1038/s41591-021-01560.
     PubMed    
     
     
     
103. O'LEARY K
     HPV vaccines beat cervical cancer.
     Nat Med. 2021 Nov 11. pii: 10.1038/d41591-021-00068.
     PubMed    
     
     
     
104. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
     BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
     Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
     PubMed     Abstract available
     
     
     
105. LEVINE-TIEFENBRUN M, Yelin I, Alapi H, Katz R, et al
     Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
     Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01575.
     PubMed     Abstract available
     
     
     
106. FENG S, Phillips DJ, White T, Sayal H, et al
     Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
     Nat Med. 2021;27:2032-2040.
     PubMed     Abstract available
     
     
     October 2021
107. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
     Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
     Nat Med. 2021 Oct 25. pii: 10.1038/s41591-021-01556.
     PubMed     Abstract available
     
     
     
108. POUWELS KB, Pritchard E, Matthews PC, Stoesser N, et al
     Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
     Nat Med. 2021 Oct 14. pii: 10.1038/s41591-021-01548.
     PubMed     Abstract available
     
     
     
109. ALI M, Khan J, Ahmad N, Khan H, et al
     COVID-19 vaccination gives hope to eradicate polio.
     Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01518.
     PubMed    
     
     
     September 2021
110. O'LEARY K
     Low-dose mRNA vaccination measures up.
     Nat Med. 2021 Sep 30. pii: 10.1038/d41591-021-00060.
     PubMed    
     
     
     
111. SHROFF RT, Chalasani P, Wei R, Pennington D, et al
     Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
     Nat Med. 2021 Sep 30. pii: 10.1038/s41591-021-01542.
     PubMed     Abstract available
     
     
     
112. CHOOKAJORN T, Kochakarn T, Wilasang C, Kotanan N, et al
     Southeast Asia is an emerging hotspot for COVID-19.
     Nat Med. 2021;27:1495-1496.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.